What is immunotherapy and does it work for Pancreatic Cancer

Understanding Immunotherapy for Pancreatic Cancer

What Is Immunotherapy?

Immunotherapy is a type of cancer treatment that works differently than traditional chemotherapy. Instead of directly killing cancer cells, immunotherapy enlists your own immune system to recognize and destroy cancer cells.

Think of it this way: Your immune system is like your body's defense force, but cancer cells are clever at hiding from it. Immunotherapy removes that disguise or "wakes up" your immune cells so they can attack the cancer.

According to research from Let's Win Pancreatic Cancer, there are several main types of immunotherapy approaches:

1. Checkpoint Inhibitors - These block proteins that cancer cells use to hide from your immune system, essentially taking the "brakes" off your immune response
2. Cancer Vaccines - Unlike flu vaccines that prevent illness, these therapeutic vaccines treat existing cancer by boosting your immune system's recognition of cancer cells
3. Adoptive T Cell Transfer - Your own immune cells are collected, enhanced, and returned to fight cancer
4. Monoclonal Antibodies - Man-made antibodies that target specific molecules on cancer cells

---

Does Immunotherapy Work for Pancreatic Cancer?

The honest answer: It's complicated, but progress is happening.

The Challenge

Pancreatic cancer is what researchers call a "cold tumor" - meaning it naturally suppresses immune responses. According to Dr. [removed] Diaz from Memorial Sloan Kettering (cited in Let's Win Pancreatic Cancer research):

"More than 95 percent of pancreas cancer patients still are unable to take advantage of immunotherapy as we know it today."

Why is pancreatic cancer so resistant to immunotherapy?

• The tumor is surrounded by dense fibrous tissue that blocks immune cells from reaching cancer cells
• Pancreatic tumors prevent recruitment of T cells (key immune fighters) that could otherwise attack the cancer
• The tumor microenvironment is filled with immunosuppressive substances that shut down immune responses

The Encouraging News

Despite these challenges, there are real breakthroughs emerging:

1. FDA Approval for Specific Patients

• Keytruda (pembrolizumab) was FDA-approved for solid tumors with high microsatellite instability or mismatch-repair deficiency
• However: Only about 3-4% of pancreatic cancer patients fit this profile

2. Combination Approaches Showing Promise

According to the 2024 CancerPatientLab webinar on Novel Therapies in Pancreatic Cancer (Dr. [removed] O'Reilly):

• CD40 agonists combined with chemotherapy show "nice added cancer shrinkage" in mid-phase studies and are moving to Phase 3 trials
• Anti-CD73 inhibitors combined with chemotherapy show early signals of potential and are also advancing to Phase 3
• Personalized neoantigen vaccines using [ID removed] technology show feasibility and early immune response signals

3. Multi-Drug Combinations

A landmark study from Johns Hopkins (published in Nature Communications, June 2023) tested three immunotherapy drugs together:

• GVAX vaccine + nivolumab + urelumab (anti-CD137 antibody)
• Patients in this combination arm showed:
  • Median disease-free survival: 33.5 months
  • Median overall survival: 35.5 months
  • These were higher than previous arms testing fewer drugs

---

Current Clinical Trial Landscape

According to Let's Win Pancreatic Cancer, researchers are actively studying:

• Vaccine combinations (GVAX + CRS-207) with and without checkpoint inhibitors
• Platform trials that test multiple immunotherapy approaches simultaneously
• KRAS-targeted vaccines - an off-the-shelf vaccine targeting the KRAS mutation found in 87% of pancreatic cancers

Dr. [removed] Vonderheide from the University of Pennsylvania states: "Clinical results we've seen with immunotherapy are unprecedented. I fully expect to see a breakthrough in how we treat pancreatic cancer within the next five to 10 years, if not sooner."

---

Key Takeaway

Immunotherapy alone hasn't been a game-changer for most pancreatic cancer patients yet. However, combination approaches - mixing immunotherapy with chemotherapy, targeted therapies, or multiple immunotherapy drugs - are showing real promise in clinical trials.

According to Dr. [removed] Strickler (Duke University, CancerPatientLab webinar): "There is some early data indicating that you may be able to use cancer vaccines to generate an antitumor immune response... but these vaccine trials are in early days. I'd say we're probably a year or two away from making them widely available."

---

Questions to Ask Your Oncologist

1. Do I have any of the specific biomarkers (like microsatellite instability) that make me eligible for FDA-approved immunotherapy?

2. Are there clinical trials combining immunotherapy with chemotherapy or other targeted therapies that I might be eligible for?

3. Has my tumor been tested for KRAS mutations, and are there KRAS-targeted immunotherapy trials available?

4. What combination approaches does my treatment team recommend for my specific situation?

5. Are there vaccine-based trials (like GVAX or personalized neoantigen vaccines) that might be appropriate for me?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.